Patent details
LUC00263
Product Name:
anifrolumab
Basic Information
- Publication number:
- LUC00263
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
-
EP097073969
- Legal Status:
- Inactive
- Application number:
- LUC00263
- First applicant's nationality:
- Procedural language:
- English
Marketing Authorization
- Marketing Authorization Number:
- EU/1/21/1623
- Marketing Authorization Type:
-
- Marketing Authorization Date:
- 15/02/2022
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 18/05/2022
- First Marketing Authorization date:
- 15/02/2022
- Grant date:
- 25/04/2025
- Activation date:
- Publication date:
- 18/05/2022
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 06/02/2034
- SPC Extension Expiration:
- 06/02/2034
- Rejection date:
- Withdrawal date:
Owner
- From:
- 18/05/2022
-
-
- Name:
- AstraZeneca AB
- Address:
- -, 151 85 Södertälje, Sweden (SE)
Agent
- Name:
- ARONOVA S.A.
- From:
- 18/05/2022
- Address:
- PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2022/07
- Publication date:
- 03/06/2022
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
2
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2025/06
- Publication date:
- 12/05/2025
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
Annual Fees
- Annual Fee Due Date:
- 28/02/2029
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-